SHR-1210 Combined With Epirubicin in the Treatment of Extensive Disease Small Cell Lung Cancer
Status:
Unknown status
Trial end date:
2020-05-31
Target enrollment:
Participant gender:
Summary
Patients with extensive disease SCLC after failure of first-line treatment were enrolled with
SHR-1210 and epirubicin for 3 cycles to evaluate initial efficacy